GlaxoSmithKline PLC GSK Annual Report 2018 on Form 20-F (0917T)
18 Marzo 2019 - 1:00AM
UK Regulatory
TIDMGSK
RNS Number : 0917T
GlaxoSmithKline PLC
15 March 2019
Issued: 15 March 2019, London UK - LSE Announcement
GlaxoSmithKline plc
Annual Report 2018 on Form 20-F
In accordance with Section 203.01 of the New York Stock Exchange
Listed Company Manual, GlaxoSmithKline plc ("GSK") announces that
on 15 March 2019 it filed with the Securities and Exchange
Commission an Annual Report on Form 20-F that included audited
financial statements for the year ended 31 December 2018. GSK's
2018 Annual Report on Form 20-F is available online at GSK's
website at www.gsk.com/corporatereporting and also online at
www.sec.gov.
Ordinary Shareholders may also elect to receive notification by
email of the publication of financial reports by registering on
www.shareview.co.uk.
A hard copy version of the GSK 2018 Annual Report, together with
the Annual Summary and Notice of Annual General Meeting will be
available on or about 2 April 2019.
Shareholders have the ability to receive, upon request, a hard
copy version of GSK's complete audited financial statements for the
year ended 31 December 2018, free of charge, by either:
(i) writing to Equiniti Limited, our registrars in the UK, at
the following address: Equiniti Limited, Aspect House, Spencer
Road, Lancing, West Sussex BN99 6DA, or by telephone on 0371 384
2991 (inside the UK) or +44 (0)121 415 7067 (outside the UK);
(ii) writing to The Bank of New York Mellon, our ADR depositary
in the US, at the following address: BNY Mellon Shareowner
Services, PO Box 505000, Louisville, KY 40233-5000, or by telephone
on +1 877 353 1154 (US toll free) or +1 201 680 6825 (outside the
US); or
(iii) contacting the GSK Response Center in the USA at +1 888 825 5249 (US toll free).
Victoria Whyte
Company Secretary
15 March 2019
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Risk factors" in the company's Annual Report on Form 20-F for
2018.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCLFFVIVFIELIA
(END) Dow Jones Newswires
March 18, 2019 03:00 ET (07:00 GMT)
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024